Lesson
Red-Eye Triage and Threat to Vision
Redness is a sign, not a diagnosis. Pain, photophobia, reduced vision, corneal change, abnormal pupil, trauma, chemical exposure, severe swelling, or contact-lens risk moves the patient out of routine self-care.
- Visual acuity
- Pain and photophobia
- Corneal threat
- Chemical exposure
- Contact-lens risk
Ask what changed, how fast, and in which eye
Move beyond routine conjunctivitis when either is prominent
Opacity, defect, irregular pupil, or trauma changes urgency
Protect the cornea before cosmetic appearance
Protect sight before treating redness
Ask about sudden or progressive vision change, deep pain, photophobia, halos, flashes, floaters, field loss, diplopia, severe headache, nausea, abnormal pupil, corneal opacity, trauma, surgery, and immune compromise. These findings can represent keratitis, uveitis, angle closure, retinal disease, open globe, orbital infection, or another urgent condition.
Treat contact-lens disease as higher risk
A lens wearer with pain, photophobia, discharge, reduced vision, corneal opacity, or marked unilateral redness requires prompt ophthalmic evaluation for keratitis. Remove the lenses, do not restart them, preserve relevant lens and solution information, and avoid cosmetic redness relief as a substitute for examination.
Irrigate chemical exposures immediately
Begin copious irrigation as soon as a chemical exposure is recognized. Do not delay for perfect substance identification. Activate emergency or poison guidance, continue based on the exposure and measured ocular pH when available, and obtain urgent examination for pain, visual change, persistent abnormality, or dangerous agents.
Use a closed urgency pathway
A mild itchy or watery eye without pain or visual change may support routine evaluation. Any mismatch, failed self-care, recurrent unilateral disease, neonatal presentation, inability to examine, or rapid deterioration requires a more urgent pathway. The decision is driven by risk to vision, not by how red the eye appears.
Quick check
Checking for saved practice…
Lesson
Infectious Conjunctivitis
Viral disease is common and usually self-limited. Bacterial, corneal, neonatal, gonococcal, chlamydial, and herpetic pathways require different treatment and urgency.
- Viral conjunctivitis
- Bacterial conjunctivitis
- Keratitis risk
- Transmission control
- Systemic infection
Support, contain spread, and recognize severe adenoviral or herpetic disease
Use therapy only when the clinical pathway supports it
Remove lenses and seek prompt ophthalmic evaluation
Use urgent systemic evaluation and treatment
Recognize common viral disease
Most acute infectious conjunctivitis in adults is viral and self-limited. Watery discharge, sequential eye involvement, respiratory symptoms, exposure, and preauricular nodes can support the diagnosis. Supportive care and infection control are appropriate when vision, cornea, pain, and systemic findings remain reassuring.
Use antibiotics for a bacterial indication
Purulent discharge and matted lids can support bacterial conjunctivitis, but overlap with viral and allergic disease is substantial. Topical antibiotics do not treat viruses. Select therapy through a clinician-guided bacterial pathway and account for age, allergy, corneal involvement, lens use, local resistance, formulation, and adherence.
Set recovery and reassessment expectations
Cold compresses and artificial tears can relieve uncomplicated symptoms. Viral cases commonly resolve within one to two weeks, although some last longer. Mild bacterial disease can resolve without antibiotics; treatment decisions depend on severity and risk. Seek reassessment for worsening symptoms or bacterial disease that has not improved after 24 hours of antibiotic use. New pain, photophobia, or persistent visual blur warrants earlier evaluation.
Use erythromycin ointment for the intended indication
For susceptible superficial ocular infection, erythromycin 0.5% ointment is labeled as an approximately 1-cm ribbon up to six times daily, with the prescribed frequency determined by severity. Keep the tube tip clear and store the reviewed product at 15-25°C. Irritation, allergy and overgrowth of nonsusceptible organisms require reassessment. This local regimen does not replace systemic treatment of gonococcal or chlamydial disease. Some listed labels retain older neonatal language; follow the CDC-based neonatal lesson for prophylaxis and treatment.
Distinguish plain tobramycin from steroid combinations
Tobramycin 0.3% solution contains an aminoglycoside without dexamethasone. For mild-to-moderate susceptible external infection, its label uses one or two drops every four hours. Severe infection may require two drops hourly under clinician direction, then reduced dosing with improvement. Stop for hypersensitivity; cross-sensitivity with other aminoglycosides can occur. Avoid contact lenses during bacterial infection. The reviewed product is stored at 2-25°C, with use below two months unestablished. An opened-bottle expiration does not determine course length.
Monitor gentamicin response and surface tolerance
Gentamicin 0.3% solution is labeled as one or two drops in affected eyes every four hours; a clinician may intensify severe infections to two drops hourly. Burning, irritation and epithelial injury can occur. Worsening discharge, inflammation or pain, or a hypersensitivity reaction, calls for stopping and contacting the clinician. Prolonged exposure can select resistant organisms or fungi. Store the reviewed product at 2-25°C without excessive heat. A topical bottle must never be injected into the eye.
Recognize neomycin sensitization during ointment treatment
Neomycin/polymyxin B/bacitracin ophthalmic ointment treats susceptible superficial infection; the reviewed label directs application every three to four hours for seven to ten days. Neomycin sensitivity may cause itching, redness, swelling or failure to heal. Stop and obtain advice if these develop rather than assuming more antibiotic is needed. Pediatric safety and effectiveness are unestablished in this label. Keep tightly closed at 15-25°C. Use the sterile ophthalmic formulation, not a skin ointment with similarly named ingredients.
Respect sulfacetamide coverage and allergy limits
Sulfacetamide 10% solution does not adequately cover Pseudomonas, Neisseria or Serratia; staphylococcal resistance also limits empiric use. Its superficial-infection label starts one or two drops every two to three hours, lengthening the interval with response, usually for seven to ten days. Sulfonamide hypersensitivity is a contraindication; rare severe reactions, including Stevens-Johnson syndrome, can occur despite the topical route. Stop for rash or hypersensitivity and seek care. Use below two months is unestablished. Store at 2-25°C and discard a darkened solution.
Separate antibiotic therapy from steroid combinations
Maxitrol contains dexamethasone as well as antibiotics. Its indication requires steroid-responsive inflammation plus bacterial infection or infection risk; it is not a routine substitute for an antibiotic in an undiagnosed red eye. Epithelial herpes simplex keratitis and fungal ocular disease are contraindications. Steroids can conceal infection and raise pressure. Prescribing and follow-up require an ocular examination.
Match azithromycin dosing to handling
AzaSite 1% uses one drop per affected eye twice daily, eight to twelve hours apart, on days one and two, then once daily on days three through seven. Invert the closed bottle and shake once before dosing. Refrigerate unopened bottles at 2-8°C; after opening, keep at 2-25°C and discard after fourteen days. That storage limit does not extend treatment. Avoid lenses during symptoms and the prescribed course. Hypersensitivity requires stopping and seeking care.
Use the combination antibiotic on its own schedule
Polymyxin B/trimethoprim solution contains 10,000 units/mL and 1 mg/mL, respectively. The reviewed Bausch + Lomb label directs one drop every three hours, at most six doses daily, for seven to ten days in mild-to-moderate susceptible surface infections. It is not indicated for ophthalmia neonatorum; safety and effectiveness below two months are unestablished. Avoid lenses during infection. Stop for hypersensitivity. Store this product at 15-25°C, protected from light, retaining its carton until use. Manufacturer-specific instructions still govern.
Distinguish the two moxifloxacin formulations
Vigamox 0.5% is labeled as one drop three times daily for seven days; its current label establishes pediatric use at all ages. The book also names Moxeza 0.5%, whose label uses one drop twice daily for seven days and does not establish use below four months. The reviewed Moxeza presentation has an ended marketing record, so verify the actual dispensed product and availability. Equal concentration does not authorize copying the other formulation’s directions. Both reviewed labels specify 2-25°C storage.
Keep the ophthalmic route distinct from injection
Moxeza has an explicit warning against intracameral administration: it can injure corneal endothelium, and intraocular moxifloxacin has been associated with toxic anterior segment syndrome. Topical bottle instructions cannot serve as an intraocular preparation protocol. For either moxifloxacin product, avoid lenses during bacterial-conjunctivitis symptoms and stop for an allergic reaction. Neonatal disease still requires prompt organism-specific assessment despite Vigamox’s age labeling.
Prepare besifloxacin suspension correctly
Besivance 0.6% is labeled as one drop three times daily, with doses four to twelve hours apart, for seven days. Invert the closed bottle and shake once before use. Safety and effectiveness below one year are unestablished. Keep at 15-25°C and protect from light. Avoid lenses throughout therapy and while infection symptoms persist. The formulation contains benzalkonium chloride; its local route does not remove contamination, intolerance, or superinfection concerns.
Separate ciprofloxacin surface and ulcer regimens
For bacterial conjunctivitis, the reviewed ciprofloxacin 0.3% solution label uses one or two drops every two hours while awake for two days, then every four hours while awake for five more days. The corneal-ulcer regimen is much more intensive: two drops every fifteen minutes for the first six hours, then every thirty minutes for the rest of day one; hourly on day two; every four hours on days three through fourteen. Continued treatment depends on corneal healing and ophthalmology review. These are distinct indications, not interchangeable intensity options.
Recognize ciprofloxacin-specific follow-up findings
White crystalline material can appear in a treated corneal ulcer. In the label’s clinical experience it did not necessarily require stopping treatment, but a new opacity still needs ophthalmic assessment rather than self-diagnosis. Burning or discomfort can occur; rash or hypersensitivity requires stopping and medical advice. The reviewed solution supports all pediatric ages and specifies 2-25°C storage with light protection. Neither age labeling nor an antibiotic bottle makes neonatal eye disease suitable for self-treatment.
Match ofloxacin frequency to the diagnosed tissue
Ofloxacin 0.3% conjunctivitis dosing is one or two drops every two to four hours on days one and two, then four times daily on days three through seven. For bacterial corneal ulcers, its label starts one or two drops every thirty minutes while awake for two days, with additional doses about four and six hours after retiring; it then uses hourly waking doses before a clinician-directed transition around days seven to nine to four daily doses until completion. The reviewed Bausch + Lomb product stores at 15-25°C; use below one year is unestablished. It is not for injection, and serious hypersensitivity remains possible.
Escalate invasive and corneal patterns
Contact-lens bacterial conjunctivitis carries keratitis risk and warrants lens removal, topical antibiotic treatment, and prompt ophthalmology evaluation. Hyperacute purulence, severe pain, corneal opacity, reduced vision, neonatal disease, genital exposure, vesicles, or zoster distribution can require urgent culture, systemic therapy, antiviral treatment, and specialist care.
Distinguish epithelial herpes from deeper inflammation
Suspected herpetic keratitis needs prompt ophthalmic examination. Active epithelial infection requires antiviral treatment; do not self-start a steroid or an antibiotic-steroid combination. Stromal or endothelial inflammation can instead require specialist-directed corticosteroids with antiviral coverage and a monitored taper. The affected corneal layer and concurrent epithelial disease determine the plan. An ophthalmologist may choose an oral antiviral rather than topical treatment; these routes are not automatically combined or substituted.
Continue ganciclovir through the healing-based course
Zirgan 0.15% gel is labeled for acute herpetic dendritic ulcers in adults and children aged two years and older. Use one drop in the affected eye five times daily, about every three hours while awake, until the ulcer heals, then three times daily for seven additional days. Healing requires clinical reassessment, not judgment from redness alone. Avoid contact lenses throughout treatment and while symptoms persist. Keep the tip clean, store at 15-25°C without freezing, and seek review for new pain or worsening inflammation. Transient blur and irritation can occur.
Treat adult inclusion conjunctivitis systemically
Persistent follicular conjunctivitis, especially after unsuccessful topical antibiotics, should prompt evaluation for chlamydia and associated genital infection. Coordinate ocular assessment, STI testing and systemic treatment rather than repeatedly changing eye drops. CDC recommends doxycycline 100 mg orally twice daily for seven days for adolescent and adult chlamydial infection; pregnancy requires a different pathway, with azithromycin 1 g orally once recommended. Arrange partner evaluation and treatment, and repeat STI testing at about three months. Persistent ocular symptoms need reassessment rather than an automatic prolonged course.
Interrupt transmission without rigid myths
Frequent handwashing, avoiding eye touching, separating towels, cleaning contaminated surfaces, and discarding contaminated cosmetics reduce spread. CDC advises staying home when systemic illness is present or close contact cannot be avoided. Return requires clinician approval and implementation of any indicated treatment, with local guidance also considered. Antibiotics are not a universal prerequisite or a guarantee that transmission has ended.
Quick check
Checking for saved practice…
Lesson
Gonococcal and Neonatal Eye Infections
Hyperacute purulence and neonatal conjunctivitis need urgent organism-specific care. Prevention, local symptoms, systemic infection and drug safety are separate decisions.
- Systemic therapy
- Neonatal evaluation
- Ceftriaxone restrictions
- Chlamydial follow-up
- Prevention versus treatment
Identify organism and extent of infection
Check bilirubin, prematurity, calcium exposure and protocol
Ocular symptoms do not justify topical-only care
Assess associated infection, adverse effects and relevant contacts
Use the ocular gonorrhea regimen
CDC recommends ceftriaxone 1 g IM once for adolescent or adult gonococcal conjunctivitis, with consideration of a single saline lavage and infectious-disease consultation. This differs from the usual lower-weight uncomplicated genital-infection dose. Arrange urgent ophthalmic care, STI testing and partner management; address possible chlamydial coinfection with appropriate systemic treatment. A topical antibiotic alone is not the management plan.
Treat neonatal gonococcal disease systemically
CDC’s isolated gonococcal ophthalmia regimen is ceftriaxone 25-50 mg/kg IV or IM once, maximum 250 mg, subject to neonatal safety review. Test for chlamydia and assess for sepsis, arthritis and meningitis; disseminated infection needs a different course. CDC lists cefotaxime 100 mg/kg IV or IM once when IV calcium prevents ceftriaxone use. Confirm availability and the neonatal specialist’s protocol rather than substituting another cephalosporin independently.
Resolve ceftriaxone restrictions before dosing
Prescribing information excludes hyperbilirubinemic neonates, premature neonates up to 41 weeks postmenstrual age, and neonates aged 28 days or less who need or are expected to need IV calcium. CDC’s ophthalmia text uses cautionary wording for hyperbilirubinemia; some institutional protocols describe carefully controlled single-dose exceptions. This discrepancy requires neonatal infectious-disease and pharmacy review. Switching to IM administration does not remove the IV-calcium concern.
Treat neonatal chlamydia beyond the eye
For neonatal chlamydial infection, CDC recommends oral erythromycin base or ethylsuccinate 50 mg/kg/day divided into four doses for fourteen days. The daily total is not the amount per dose. Topical therapy alone is inadequate. Follow up for response because another course may be needed, assess for associated pneumonia, and arrange maternal and partner care. Oral erythromycin and azithromycin in infants younger than six weeks have been associated with hypertrophic pyloric stenosis; monitor for its signs. Evidence for short-course azithromycin in ophthalmia is limited.
Keep prevention separate from treatment
Birth prophylaxis with erythromycin 0.5% ointment protects against gonococcal ophthalmia; it does not prevent chlamydial ophthalmia or pneumonia. Prior prophylaxis does not rule out infection when discharge develops. An asymptomatic infant exposed to maternal chlamydia needs reliable monitoring rather than automatic empiric treatment under CDC guidance.
Quick check
Checking for saved practice…
Lesson
Allergic Conjunctivitis
Bilateral itching, watery tearing, allergen exposure, and connected rhinitis or asthma support allergy. Pain, photophobia, reduced vision, or corneal findings demand another explanation.
- Itch-dominant pattern
- Allergen exposure
- Topical dual-action therapy
- Lens and cosmetic triggers
- Rhinitis connection
Match pollen, animal, dust, mold, cosmetic, or lens exposure
Connect itch and tearing to a mechanism
Use exact-label ocular antihistamine or mast-cell treatment
Send atypical features down another pathway
Use itching as the anchor
Prominent bilateral itching with watery tearing, chemosis, seasonal or environmental exposure, and rhinitis strongly supports allergic conjunctivitis. Thick purulence, severe unilateral pain, photophobia, reduced vision, corneal opacity, vesicles, or marked lid tenderness requires a different pathway.
Reduce clinically relevant exposure
Identify pollen, animal, dust, mold, cosmetic, contact-lens, or solution exposure that matches symptom timing. Cold compresses, avoiding eye rubbing, hand and face washing after exposure, lens review, and targeted environmental control can reduce burden without broad unsupported avoidance.
Target local histamine signaling
Topical antihistamine and dual antihistamine mast-cell agents can provide focused relief. Use the exact product label for age, frequency, lens instructions, preservatives, and storage. Oral second-generation antihistamines may help connected rhinitis but can worsen dryness in some patients.
Differentiate familiar products
Ketotifen, olopatadine, and azelastine are encountered as ophthalmic options for allergic itching, but concentration, prescription status, frequency, age, preservative, and contact-lens instructions depend on the exact product. Current ketotifen and olopatadine labels warn against treating contact-lens irritation and require lens removal before use. Burning, temporary blur, dryness, or irritation can occur, while eye pain, visual change, worsening redness, or persistent symptoms require reassessment.
Match olopatadine strength to its schedule
The reviewed OTC Pataday labels permit use from age two years; younger children need a doctor. Olopatadine 0.1% uses one drop per affected eye twice daily, six to eight hours apart, at most twice daily. The 0.2% and 0.7% products use one drop once daily, at most once daily. Remove lenses and wait at least ten minutes before reinsertion; do not wear them in a red eye. These products do not treat lens-related irritation. Separate other eye products by at least five minutes. Store 0.1% at 4-25°C and the reviewed once-daily products at 2-25°C.
Read ketotifen concentration and age correctly
Zaditor contains ketotifen 0.025%, equivalent to ketotifen fumarate 0.035%; these are two expressions of the same labeled formulation. For ages three years and older, use one drop per affected eye twice daily, eight to twelve hours apart, at most twice daily. Younger children need a doctor. Remove lenses and wait at least ten minutes before reinsertion; do not use it for lens-related irritation. Store the reviewed product at 4-25°C. Stop and seek advice for eye pain, vision changes, redness, or itching that worsens or persists beyond 72 hours.
Use a stop rule for OTC allergy drops
The reviewed Pataday labels require stopping and medical advice for eye pain, vision change, increased redness, or itching that worsens or lasts more than 72 hours. Reject cloudy or discolored solution and protect the dropper tip from contact. A lens-reinsertion interval is not permission to resume lenses when the eye remains red or painful. Persistent symptoms warrant reassessment rather than extra doses or combining multiple allergy drops.
Include once-daily alcaftadine
Lastacaft alcaftadine 0.25% is available OTC for temporary allergy-related itching. Its Drug Facts directs one drop per affected eye once daily from age two years; younger children need a doctor. Separate other eye products by at least five minutes. Remove lenses, wait at least ten minutes before reinsertion, and do not wear lenses in a red eye or use this product for lens irritation. Store at 15-25°C. Stop for pain, vision changes, increased redness, or itching that worsens or persists beyond 72 hours.
Distinguish ophthalmic azelastine from nasal products
Prescription azelastine hydrochloride 0.05% ophthalmic solution treats allergic eye itching with one drop per affected eye twice daily. Safety and effectiveness below age three years are unestablished. It is for ocular use; nasal azelastine is not a substitute. Brief burning or stinging and bitter taste can occur. Remove soft lenses and wait at least ten minutes before reinsertion, provided the eye is not red; do not use it for lens-related irritation. The reviewed Alembic product stores upright at 2-25°C. Hypersensitivity to a component is a contraindication, and pregnancy or breastfeeding requires individualized benefit-risk review.
Use cromolyn as scheduled vernal-disease therapy
Cromolyn sodium 4% ophthalmic solution is a mast-cell stabilizer labeled for vernal conjunctivitis, keratoconjunctivitis and keratitis. Its regimen is one or two drops in each eye four to six times daily at regular intervals. Improvement often begins within days but can require up to six weeks; it is not an immediate rescue drop. Use below age four years is unestablished. Avoid contact lenses throughout treatment. Brief stinging can occur; hypersensitivity requires medical attention. The reviewed Sandoz product stores at 15-30°C in its original carton, protected from light. Corneal involvement and any adjunctive steroid require eye-care supervision.
Recognize the historical nedocromil option
The book lists Alocril nedocromil 2%, a mast-cell stabilizer for allergic conjunctival itching. Its reviewed label uses one or two drops in each eye twice daily at regular intervals throughout allergen exposure, even when symptoms are absent; use below age three years is unestablished. Patient instructions prohibit lenses during treatment and specify 2-25°C storage in the original carton. Headache, ocular irritation and unpleasant taste can occur. This Allergan presentation has a September 2022 marketing-end record. Verify availability and an appropriate alternative instead of assuming an old brand listing can be dispensed.
Handle cetirizine eye solution as a single-use product
Zerviate cetirizine 0.24% ophthalmic solution treats allergic ocular itching with one drop per affected eye twice daily, about eight hours apart. Pediatric use is established from age two years. The reviewed Harrow presentation uses single-use containers: open immediately before dosing, use for both eyes if prescribed, then discard all remaining solution. Keep unopened containers in their original foil pouch at 15-25°C. This formulation contains benzalkonium chloride despite its single-use packaging. Remove lenses and wait ten minutes before reinsertion; avoid lenses if the eye is red. Instillation pain, redness or reduced visual acuity warrant assessment in context.
Continue epinastine through relevant exposure
Epinastine hydrochloride 0.05% ophthalmic solution prevents allergic conjunctival itching. Its label uses one drop in each eye twice daily throughout allergen exposure, even when symptoms are absent. Use below age two years is unestablished. Remove contact lenses and wait ten minutes before reinsertion; do not wear lenses in a red eye or use the medicine for lens-related irritation. Burning, redness, itching and increased tearing can occur. The reviewed Somerset product stores at 20-25°C, with excursions to 15-30°C permitted. Keep its bottle tightly closed and the tip free from contact.
Place lodoxamide in the vernal-disease pathway
The book also lists Alomide lodoxamide 0.1%, a mast-cell stabilizer historically labeled for vernal conjunctivitis, keratoconjunctivitis and keratitis. It should not be treated as an interchangeable OTC itch-relief drop. Vernal disease with corneal involvement requires ophthalmic assessment and an individualized treatment plan. The FDA 2026 Orange Book lists US Alomide 0.1% as discontinued. Retain it as historical coverage, not a routinely available treatment option; verify current product status and prescribing information before any proposed use.
Avoid cosmetic-only escalation
Vasoconstrictor redness drops reduce visible vessel dilation but do not control the allergic cascade and can add rebound or surface irritation. Persistent or severe symptoms need diagnostic reassessment, not repeated whitening products or unsupervised ocular steroids.
Quick check
Checking for saved practice…
Lesson
Blepharitis, Meibomian Dysfunction, and Demodex
Chronic lid-margin disease destabilizes the tear film and can reflect anterior debris, meibomian dysfunction, rosacea, or Demodex infestation.
- Anterior blepharitis
- Meibomian glands
- Lid hygiene
- Rosacea
- Demodex collarettes
Sustain lid hygiene rather than one-time cleaning
Warm, mobilize, and restore the lipid layer
Identify a specific parasite-linked phenotype
Treat connected surface and skin drivers
Locate disease at the lid margin
Anterior blepharitis can produce crusting, lash debris, burning, redness, and morning sticking. Posterior disease and meibomian gland dysfunction produce capped openings, thick secretions, lid telangiectasia, evaporation, fluctuating vision, and recurrent chalazia. Rosacea and dry eye commonly overlap.
Build sustainable lid care
Warm compresses, lid hygiene, and appropriate massage can loosen debris and improve gland expression. Technique, temperature, frequency, skin tolerance, dexterity, and adherence matter. Chronic disease often relapses, so care is adjusted over time rather than presented as a one-time cure.
Recognize Demodex phenotype
Collarettes at the lash base are a useful clue to Demodex blepharitis. Current FDA labeling includes lotilaner ophthalmic solution for Demodex blepharitis. It is dosed by its exact label, includes contact-lens and contamination counseling, and should not be replaced by improvised ocular tea-tree exposure.
Make lid hygiene reproducible
Wash hands, then apply a clean cloth moistened with comfortably warm water to the closed lid for a few minutes to loosen crusts. Gently clean along the lash margin with the clinician-recommended gentle cleanser, remove residue, and use a fresh cloth or swab for the other eye. Avoid hot compresses or forceful rubbing. Continue a sustainable routine and address associated rosacea or dandruff; recurrent symptoms do not automatically mean an antibiotic is needed.
Use the full lotilaner course for confirmed Demodex disease
Xdemvy lotilaner 0.25% is labeled as one drop in each eye twice daily, about twelve hours apart, for six weeks. If a dose is missed, continue with the next scheduled dose. Separate other topical eye medicines by at least five minutes. Remove contact lenses and wait fifteen minutes before reinsertion. Store at 15-25°C; the label permits use of an opened bottle until its printed expiration, but this does not extend the prescribed course. Stinging or burning can occur. New ocular infection, trauma, surgery or ocular reactions require prompt prescriber advice about continued use. Safety and effectiveness below age eighteen years are unestablished.
Escalate complicated disease
Corneal involvement, reduced vision, marked pain, recurrent severe inflammation, lash loss, lid distortion, treatment failure, or uncertain diagnosis requires eye-care evaluation. Antibiotic, anti-inflammatory, antiparasitic, and gland-directed procedures are selected through the confirmed subtype.
Quick check
Checking for saved practice…
Lesson
Dry-Eye Foundations
Dry eye is a tear-film and ocular-surface disorder shaped by aqueous supply, evaporation, inflammation, blinking, lids, nerves, environment, medicines, and systemic disease.
- Tear-film layers
- Aqueous deficiency
- Evaporative disease
- Reflex tearing
- Environmental burden
Recognize lacrimal and autoimmune contributors
Assess lids, glands, blink, airflow, and screens
Maintain a wettable epithelial interface
Do not force every symptom to match one sign
Think beyond tear quantity
The tear film depends on aqueous, lipid, mucin, epithelial, and neural systems. Dryness, burning, grittiness, fatigue, fluctuating vision, redness, and even excessive tearing can arise when the surface is unstable. Reflex tearing does not prove that the ocular surface is healthy.
Separate aqueous and evaporative drivers
Aqueous deficiency can accompany lacrimal dysfunction and autoimmune disease. Evaporative disease is linked to meibomian dysfunction, incomplete blinking, screen use, airflow, low humidity, smoke, and lens wear. Many patients have mixed disease, so examination and history guide layered treatment.
Audit medicines and systemic disease
Review anticholinergic burden, systemic antihistamines, isotretinoin, diuretics and selected anxiolytic or hypnotic medicines, including benzodiazepines. These are possible contributors, not proof that a medicine caused an individual patient's symptoms. Consider timing, dose changes and competing causes with the prescriber before changing treatment. Sjogren disease, thyroid disease, diabetes and prior ocular surgery matter. Parkinson disease can impair blinking, while rosacea and other skin disorders can accompany meibomian gland dysfunction; inspect lid closure and the ocular surface rather than treating every case as isolated tear deficiency.
Make environmental care practical
Reduce direct fan or air-conditioning flow, avoid smoke, use a humidifier in dry rooms, and take regular breaks from prolonged screen viewing. Wraparound sunglasses can reduce outdoor wind exposure. If a medicine contributes to dryness, discuss an alternative with its prescriber rather than stopping it independently. Persistent symptoms deserve examination of tear production, tear stability and eyelid structure. Punctal plugs reduce tear drainage; they are an eye-care procedure, distinct from temporary finger pressure used during drop administration.
Begin with mechanism-matched foundations
Use blink breaks, environment changes, lens review, lid care, and sterile lubricants according to the patient phenotype. Persistent pain, photophobia, reduced vision, corneal findings, marked asymmetry, severe autoimmune symptoms, or discordant symptoms and signs warrants focused eye evaluation.
Quick check
Checking for saved practice…
Lesson
Dry-Eye Pharmacotherapy
Therapy is layered from sterile lubrication and exposure control to anti-inflammatory and tear-pathway treatment chosen by phenotype, product, tolerability, and response.
- Artificial tears
- Preservative burden
- Lifitegrast
- Cyclosporine
- Treatment expectations
Choose viscosity, preservative burden, and frequency
Set onset and tolerability expectations
Use product-specific delivery and labeling
Confirm technique, adherence, lids, environment, and cornea
Select a sterile lubricant
Artificial tears differ in viscosity, lipid content, osmoprotectants, preservatives, container, blur, and duration. Frequent use or surface intolerance can favor preservative-free units, but every product still requires sterile handling. Check FDA alerts and stop a product if discharge, pain, vision change, or unexpected discomfort develops.
Read the lubricant ingredients, not just the brand
Artificial tears are a product family, not one formulation. Examples include dextran 70, glycerin, hypromellose and propylene glycol; some emulsions also contain mineral oil. The reviewed Artificial Tears product combines dextran 70 0.1%, glycerin 0.2% and hypromellose 0.3%. Preserved Systane Complete instead lists propylene glycol 0.6% as its active lubricant, with mineral oil among its inactive ingredients. Check the exact formulation, preservative and container rather than assuming every product under a familiar brand is identical.
Give lubricants a reassessment rule
These two reviewed lubricant labels direct shaking and one or two drops in affected eyes as needed. Follow the actual package rather than applying that instruction to every artificial tear. Stop and seek advice for eye pain, vision change, persistent redness or irritation, worsening symptoms, or symptoms lasting more than 72 hours. Significant pain or vision loss needs prompt assessment rather than waiting three days. Chronic dry-eye care may continue under an established clinician-directed plan.
Set expectations for lifitegrast
Xiidra lifitegrast 5% treats dry-eye signs and symptoms: one drop in each eye twice daily, about twelve hours apart. Use a vial immediately after opening, dose both eyes, and discard the remainder. Remove lenses and wait fifteen minutes before reinsertion. Keep unopened vials in their foil pouch at 20-25°C. Safety and efficacy below seventeen years are unestablished. Irritation, altered taste, and transient blur can occur. Wheezing, breathing difficulty, or tongue swelling requires immediate medical care; known ingredient hypersensitivity contraindicates use. Human pregnancy and lactation data are lacking, so review individual circumstances. LFA-1 blockade interferes with inflammatory cell interactions, although the exact dry-eye mechanism remains uncertain.
Use cyclosporine by exact formulation
Ophthalmic cyclosporine products reduce ocular-surface inflammation through formulation-specific concentrations and vehicles. They are not automatically interchangeable. Teach the exact product preparation, contact-lens instructions, spacing, storage, onset expectations, and response plan.
Prepare Restasis emulsion before dosing
Restasis 0.05% is labeled to increase tear production suppressed by inflammation associated with keratoconjunctivitis sicca. For the single-use vial, invert a few times to obtain a uniform white emulsion, then instill one drop in each eye twice daily about twelve hours apart. Discard immediately after dosing. Separate lubricant drops by fifteen minutes and remove contact lenses, waiting fifteen minutes before reinsertion if lens wear is appropriate. Store at 15-25°C. Burning can occur; hypersensitivity is a contraindication. The labeled trial benefit was measured at six months, so this is not an immediate lubricant substitute.
Interpret Restasis population evidence precisely
For single-use Restasis, safety and efficacy below sixteen years are unestablished. Its label reports undetectable blood concentrations and does not expect fetal exposure; that does not establish safety for every ocular medicine. Milk exposure after topical use has not been studied, so weigh breastfeeding benefits and maternal need with the clinician. Increased tear production was not demonstrated in trial participants using topical anti-inflammatory drugs or punctal plugs; this is an evidence limitation, not an additional labeled contraindication.
Prepare the Restasis MultiDose bottle separately
Restasis MultiDose 0.05% uses a preservative-free reusable bottle. Before first use, check the shipping cover and pull tab; do not use damaged or missing seals. Remove the cover, tab and protective cap, then prime two drops onto a tissue without touching it. Before each dose, invert the bottle several times to mix. Use one drop in each eye twice daily about twelve hours apart and recap. Separate lubricants by fifteen minutes; remove lenses and wait fifteen minutes before reinsertion when lens wear is appropriate. Store at 15-25°C; the current label permits use after opening until the bottle expiration. Evidence below sixteen years is unestablished. Do not apply this reusable-bottle instruction to single-use vials.
Keep Cequa solution instructions separate
Cequa 0.09% solution increases tear production in keratoconjunctivitis sicca. Use one drop in each eye twice daily about twelve hours apart, separate artificial tears by fifteen minutes, and discard the single-use vial after dosing both eyes. Remove contact lenses and wait fifteen minutes before reinsertion. Use below age eighteen years is unestablished. Instillation pain and conjunctival redness are common adverse effects. Store Cequa vials at 20-25°C in their original foil pouch. Its pivotal tear-production assessment was at day 84; do not interpret that trial time point as a guaranteed onset or compare it directly with another product’s trial to rank efficacy.
Teach Vevye bottle delivery explicitly
Vevye cyclosporine 0.1% is a preservative-free, nonaqueous solution for signs and symptoms of dry-eye disease. Use one drop in each eye twice daily about twelve hours apart. Check the tamper-evident ring before first use, wash hands and avoid tip contact. Pull the lower lid down, invert the bottle and allow a drop to dispense; if none appears after a few seconds, apply slight pressure. If the drop misses the eye, try again. Recap tightly after dosing. The drop may not be felt, so sensation alone is not a reason to add more. Separate other eye drops by fifteen minutes. Remove contact lenses and wait fifteen minutes before reinsertion. Store at 15-25°C without refrigeration or freezing; an opened bottle may be used until its printed expiration. Use below eighteen years is unestablished. Instillation reactions and temporary visual changes can occur.
Target evaporation with perfluorohexyloctane
Miebo 100% perfluorohexyloctane treats dry-eye signs and symptoms. Its tear-surface layer is expected to reduce evaporation; the exact therapeutic mechanism is uncertain. Instill one drop four times daily in affected eyes as prescribed. Remove lenses and wait at least thirty minutes before reinsertion. To dispense, gently squeeze the upright uncapped bottle, invert while squeezing, release pressure to draw air in, then squeeze again over the eye. Temporary blur or redness can occur. Prior hypersensitivity to perfluorohexyloctane contraindicates use. Store at 15-25°C; after opening, use only through the printed expiration. Safety and effectiveness below eighteen years are unestablished.
Stimulate tears through the nasal route
Tyrvaya varenicline nasal spray treats dry-eye signs and symptoms through a neural tear-production pathway. Give one 0.03-mg spray in each nostril twice daily, about twelve hours apart. Prime a new bottle with seven sprays away from faces; after more than five unused days, re-prime once. Do not shake. Aim toward the same-side ear without touching the nasal wall, place the tongue against the palate, and breathe gently during spraying. Wipe the applicator and replace its clip and cap. Sneezing, cough and nasal or throat irritation are common. Skip a missed dose and resume the schedule. Store at 20-25°C without freezing; discard thirty days after opening. Each bottle supplies fifteen treatment days; finish it before opening the second. Pediatric use is unestablished.
Keep acoltremon storage deadlines separate
Tryptyr acoltremon 0.003% is a TRPM8 agonist for dry-eye signs and symptoms; the exact therapeutic mechanism remains uncertain. Use one drop in each eye twice daily, about twelve hours apart. Separate other drops by at least five minutes, remove lenses and wait fifteen minutes before reinsertion. Resume the next scheduled dose after a missed dose. Instillation pain is common; new or concerning eye symptoms require prescriber contact. Pediatric use is unestablished. Refrigerate unopened cartons at 2-8°C. The prescribing information permits 2-25°C after opening, with a thirty-day limit at room temperature. Keep unused vials in their foil pouch and discard them seven days after pouch opening. An opened vial is for immediate dosing and disposal. Observe all printed expirations and any stricter dispensed-package instructions.
Limit Eysuvis to its prescribed short course
Eysuvis loteprednol 0.25% suspension treats dry-eye signs and symptoms for up to two weeks: one to two drops in each eye four times daily as prescribed. Shake for two to three seconds. Separate other drops by at least five minutes; remove lenses and wait fifteen minutes before reinsertion. Initial prescribing and renewal require ocular examination; renewal also requires pressure evaluation. Steroid risks include impaired healing, infection, cataract and increased pressure. Epithelial herpes, ocular mycobacterial infection and fungal ocular disease are contraindications. Store upright at 15-25°C without freezing. The bottle may remain usable until expiration, but that does not authorize prolonged treatment. Pediatric safety and effectiveness are unestablished.
Escalate by phenotype, not frustration
Persistent disease may require tear-stimulating options, short clinician-supervised anti-inflammatory bridging, punctal strategies, gland treatment, scleral lenses, autoimmune care, or neuropathic-pain evaluation. Recheck diagnosis, lids, cornea, environment, medicines, technique, access, and adherence before labeling disease refractory.
Quick check
Checking for saved practice…
Lesson
Ocular Inflammation and Steroid Boundaries
Topical corticosteroids and NSAIDs can be valuable in defined ocular disease but can also worsen infection, raise pressure, delay healing, or injure a vulnerable cornea.
- Diagnostic control
- Ocular corticosteroids
- Ophthalmic NSAIDs
- Pressure and cataract
- Corneal safety
Do not treat an undiagnosed red eye with leftovers
Respect contraindications; selected infectious inflammation needs specialist-directed treatment
Track intraocular pressure and cataract risk
Follow the prescribed course, reassessment and taper instructions
Do not treat an undiagnosed red eye with steroids
Ocular corticosteroids can suppress visible inflammation while worsening herpes, fungal disease, bacterial keratitis, or epithelial injury. Leftover drops, borrowed products, and combination antibiotic steroid products are unsafe substitutes for examination when pain, photophobia, vision change, corneal disease, or uncertain diagnosis is present.
Confirm prednisolone strength and handling
Pred Forte is prednisolone acetate 1% suspension; Pred Mild is 0.12%. Pred Forte treats steroid-responsive anterior ocular inflammation; Pred Mild is labeled for mild-to-moderate noninfectious allergic and inflammatory disease. Both require shaking. Their usual labeled schedule is one or two drops two to four times daily, with clinician-directed intensification during the first 24-48 hours. Follow the prescribed course. Store Pred Forte upright at up to 25°C and Pred Mild upright at 15-25°C; protect both from freezing.
Distinguish Omnipred and its labeled formulation
Omnipred is prednisolone acetate 1% suspension. The reviewed Omnipred and Sandoz authorized-generic labels specify shaking well and two drops in affected eyes four times daily, with clinician-directed reduction and gradual withdrawal for chronic treatment. Store upright at 8-24°C; the opened bottle may be used until expiration, which does not authorize an extended treatment course. These instructions differ from Pred Forte despite the same active concentration. Verify the actual dispensed label. Both formulations reviewed here contain benzalkonium chloride; their ingredient lists do not include the sodium bisulfite found in Pred Forte.
Apply Omnipred safety boundaries
The steroid infection, healing, cataract and pressure risks still apply. Initial prescribing and renewal require examination; use for ten days or longer requires pressure monitoring. The patient instructions direct stopping and contacting the physician if pain or inflammation worsens or persists beyond 48 hours. Epithelial herpes, fungal or mycobacterial ocular disease and relevant hypersensitivity contraindicate use. Pediatric safety and effectiveness are unestablished; very frequent ophthalmic prednisolone can cause adrenal suppression, particularly in young children. Pregnancy and breastfeeding require individualized review.
Do not equate a lower steroid strength with no risk
Both prednisolone labels require routine pressure monitoring with use for ten days or longer. They contraindicate untreated purulent infection, epithelial herpes simplex keratitis, fungal or mycobacterial ocular disease, and relevant hypersensitivity. Cataract, pressure elevation, secondary infection and impaired healing remain concerns with Pred Mild. Both contain sodium bisulfite, which can provoke serious reactions in susceptible patients.
Reassess prednisolone response and lens use
Arrange examination before starting or renewing ocular steroid treatment; failure to improve after two days requires reassessment. Worsening symptoms warrant earlier contact. Both prednisolone products contain benzalkonium chloride: remove soft lenses and wait fifteen minutes before reinsertion when lens wear is otherwise appropriate. Keep the tip clear and do not share bottles.
Distinguish Maxidex suspension from other dexamethasone products
Maxidex 0.1% is a topical dexamethasone suspension without an antibiotic. Shake before dosing. Its label uses one or two drops, up to four to six times daily for mild disease; severe disease may require hourly dosing followed by a clinician-directed taper. Examine before starting or refilling, reassess no improvement after two days, and monitor pressure with use of ten days or longer. Untreated bacterial infection, epithelial HSV, fungal and mycobacterial disease are contraindications. Selected infectious inflammation requires specialist management, not self-treatment. Remove soft lenses before administration. Store upright at 8-27°C; opened-bottle usability through expiration does not authorize prolonged treatment. Excessive dosing can cause systemic steroid effects, including adrenal suppression, particularly in children or patients taking CYP3A4 inhibitors.
Separate FML strengths from Flarex
FML 0.1% and FML Forte 0.25% contain fluorometholone; Flarex 0.1% contains fluorometholone acetate. All are suspensions requiring shaking. The FML labels use one drop two to four times daily, with prescriber-directed dosing every four hours during the first 24-48 hours if needed. Flarex uses one or two drops four times daily; a prescriber may intensify the initial 24-48 hours to two drops every two hours. Do not substitute one schedule or formulation for another.
Retain pressure monitoring with fluorometholone
A slower average pressure response than dexamethasone in small studies does not establish freedom from glaucoma risk. FML labels describe significant rises within one week in some patients; Flarex describes rises within three days. These products require routine pressure monitoring with use for ten days or longer, with earlier assessment according to risk. Infection, impaired healing, cataract and tissue-thinning risks remain. Epithelial HSV, fungal and mycobacterial ocular disease are contraindications; check the exact label and diagnosis.
Counsel fluorometholone handling and reassessment
Store these suspensions upright at 2-25°C, protected from freezing. Remove soft lenses and wait at least fifteen minutes before reinsertion when wear is appropriate. FML and FML Forte use below age two is unestablished; Flarex pediatric safety and effectiveness are unestablished. Arrange reassessment if symptoms fail to improve after two days; do not wait two weeks with persistent or worsening inflammation. FML labels direct stopping and contacting the clinician for inflammation or pain beyond 48 hours or aggravation. Follow clinician-directed withdrawal, particularly after chronic treatment.
Recognize the historical FML ointment formulation
RxPrep also lists fluorometholone ointment. ASHP reports that AbbVie discontinued FML 0.1% ophthalmic ointment; that report does not apply to the suspension. The archived FDA ointment label describes an approximately half-inch ribbon one to three times daily, rather than a drop-based regimen. Treat this as historical formulation literacy, not a current supply recommendation. If an old prescription calls for it, verify availability and obtain a prescriber-selected alternative with new formulation-specific directions.
Keep Alrex allergy treatment distinct
Alrex loteprednol etabonate 0.2% suspension provides temporary relief of seasonal allergic conjunctivitis under clinician direction. Shake vigorously and use one drop in affected eyes four times daily. Reassess failure to improve after two days; monitor pressure with use of ten days or longer and examine before renewal beyond fourteen days. Steroid infection, cataract and healing risks remain despite metabolism to inactive products. Do not use for contact-lens irritation or wear lenses while the eye is red. If lens wear is otherwise appropriate and the eye is not red, remove soft lenses and wait at least ten minutes after dosing before reinsertion. Store upright at 15-25°C without freezing. Pediatric safety and effectiveness are unestablished. Do not transfer Eysuvis or Lotemax directions to Alrex.
Check Lotemax suspension indication and potency
Lotemax 0.5% suspension covers selected steroid-responsive inflammation as well as postoperative inflammation. Shake vigorously. The usual dose is one or two drops four times daily; for steroid-responsive disease, only the prescriber may intensify initial treatment. The postoperative schedule starts 24 hours after surgery and continues through the first two weeks. Reassess nonresponse after two days and monitor pressure with use of ten days or longer. It is less effective than prednisolone acetate 1% for acute anterior uveitis and should not replace a more potent steroid when one is needed. Avoid soft contact lenses during use. Store upright at 15-25°C without freezing. Pediatric safety and effectiveness are unestablished.
Recognize the Lotemax SM schedule
Lotemax SM is 0.38% submicron gel for postoperative inflammation and pain. Its dose is one drop three times daily from the day after surgery through the first two postoperative weeks. Invert the closed bottle and shake once to fill the tip. Store upright at 15-25°C; the bottle expiration does not extend the prescribed course. Do not wear contact lenses while the eyes are inflamed. Pediatric safety and effectiveness are unestablished. Steroid infection, cataract and healing risks remain; monitor pressure with use of ten days or longer and obtain an eye examination before prescribing or renewing. Do not substitute the 0.5% gel schedule automatically.
Use Lotemax gel by its own directions
Lotemax 0.5% gel treats postoperative inflammation and pain. Invert the closed bottle and shake once to fill the tip; instill one or two drops four times daily from the day after surgery through the first two postoperative weeks. Store upright at 15-25°C. Its pediatric safety and effectiveness are established; this does not establish pediatric use for every loteprednol formulation.
Distinguish Lotemax ointment from gel
For postoperative inflammation and pain, Lotemax 0.5% ointment uses approximately a half-inch ribbon four times daily, starting 24 hours after surgery through the first two postoperative weeks. Wash hands and avoid touching the tube tip. Store at 15-25°C; the opened-tube expiration is not permission to extend treatment. Pediatric safety and effectiveness are unestablished.
Keep postoperative loteprednol precautions
Neither Lotemax 0.5% gel nor ointment permits contact lenses during treatment. Both retain steroid-related pressure, cataract, infection and impaired-healing risks; monitor pressure when used for ten days or longer. Their contraindications include epithelial herpes simplex keratitis and fungal or mycobacterial ocular infection. Worsening pain or inflammation needs prompt assessment. Ointment labeling also requires reassessment if symptoms do not improve after two days.
Identify the exact tobramycin-dexamethasone product
TobraDex ST suspension contains tobramycin 0.3% with dexamethasone 0.05%. Its usual labeled dose is one drop every four to six hours; a prescriber may intensify the first 24-48 hours to every two hours, then reduce frequency with improvement. Shake well. It treats steroid-responsive inflammation with bacterial infection or risk, not undifferentiated pink eye. Do not wear contact lenses. Store upright, protected from light, at 2-25°C. Check pressure and examine the eye before starting or renewing; monitor pressure with use of ten days or longer and reassess failure to improve after two days.
Do not transfer older TobraDex instructions to ST
The older branded TobraDex suspension label describes tobramycin 0.3% plus dexamethasone 0.1%, one to two drops every four to six hours, and storage at 8-27°C. The reviewed Novartis listing records marketing ending in 2024; it is a historical formulation reference, not proof of current availability. Verify the dispensed product and its current instructions. An antibiotic component does not remove steroid contraindications or infection, cataract, healing and pressure risks.
Control pressure and duration
Topical steroids can raise intraocular pressure and contribute to cataract, delayed healing, and secondary infection. Risk varies by drug, potency, route, frequency, duration, patient susceptibility, and glaucoma history. Clinician-directed courses need an explicit stop or taper plan and appropriate monitoring.
Distinguish intravitreal implants from surface drops
Ozurdex is a 0.7-mg dexamethasone implant placed into the vitreous by an eye specialist. Its indications include macular edema after retinal vein occlusion, diabetic macular edema and noninfectious posterior-segment uveitis. It is not a self-administered steroid drop. Contraindications include ocular or periocular infection, ingredient hypersensitivity, glaucoma with a cup-to-disc ratio greater than 0.8, and a torn or ruptured posterior lens capsule. Prior laser posterior capsulotomy in a pseudophakic eye is not itself a contraindication. Follow-up must assess pressure and injection complications, including endophthalmitis and retinal detachment; cataract is another steroid risk. New pain, redness, light sensitivity or vision change after treatment requires immediate ophthalmic care.
Verify the exact bromfenac 0.09% product
The reviewed Alembic 0.09% label uses one drop once daily starting one day before cataract surgery, including surgery day, through fourteen postoperative days. Historical Xibrom 0.09% used one drop twice daily starting 24 hours after surgery for two weeks. Concentration alone does not establish the schedule: verify the dispensed product and prescription. For the reviewed once-daily product, separate drops by five minutes, avoid contact lenses during use, and store at 15-25°C. It contains sodium sulfite; the NSAID corneal, bleeding, healing and sensitivity precautions apply. Use below age eighteen is unestablished; avoid late-pregnancy use.
Distinguish Prolensa from BromSite
Prolensa 0.07% uses one drop once daily for cataract-surgery inflammation and pain reduction. BromSite 0.075% uses one drop twice daily, morning and evening, for postoperative inflammation and pain prevention. Both start one day before surgery, include surgery day, and continue for fourteen days afterward. Separate Prolensa from other drops by at least five minutes; give BromSite at least five minutes after other topical eye medicines. Before each BromSite dose, invert the closed bottle and flick firmly once to fill the tip. Store both at 15-25°C. Discard BromSite after treatment ends.
Apply bromfenac formulation precautions
Both products require review of NSAID sensitivity, bleeding risk and corneal disease. Delayed healing can worsen with topical steroids; epithelial breakdown requires immediate discontinuation and close ophthalmic monitoring. Avoid extending the surgical course without reassessment. Prolensa contains sodium sulfite, which can trigger serious reactions in susceptible patients. Remove lenses before Prolensa and wait ten minutes before reinsertion only when postoperative lens wear is otherwise permitted. BromSite instructions advise against lens wear during use. Pediatric use is unestablished for both; avoid late-pregnancy use.
Match diclofenac to the surgical procedure
Diclofenac 0.1% ophthalmic solution treats cataract-surgery inflammation with one drop four times daily, starting 24 hours after surgery through the first two postoperative weeks. For corneal refractive surgery pain and photophobia, use one or two drops within the hour before surgery, again within 15 minutes afterward, then four times daily for up to three days. These schedules are procedure-specific. Its label calls for one year of monitoring after refractive surgery because refractive stability is unestablished.
Apply diclofenac corneal and lens precautions
Epithelial breakdown requires immediate discontinuation and close ophthalmic monitoring. Review corneal disease, diabetes, rheumatoid arthritis, repeat surgery, NSAID sensitivity, bleeding risk and concurrent topical steroids. Do not use with soft contact lenses except a clinician-directed bandage hydrogel lens during the first three days after refractive surgery. Use separate bottles for bilateral surgery. The reviewed Bausch + Lomb product is stored at 20-25°C protected from light. Pediatric use is unestablished; avoid late-pregnancy use.
Use flurbiprofen for intraoperative miosis prevention
Flurbiprofen 0.03% ophthalmic solution inhibits pupil constriction during surgery. Give four doses total: one drop approximately every 30 minutes, beginning two hours before surgery. This is not a four-times-daily postoperative pain regimen. Review ingredient hypersensitivity, aspirin/NSAID sensitivity, bleeding risk and delayed healing, particularly with topical steroids. Use a separate bottle for each eye in bilateral surgery. The reviewed formulation contains thimerosal and is stored at 15-25°C. Pediatric safety and effectiveness are unestablished; pregnancy and lactation require individualized review.
Match Acular to its indication
Acular ketorolac 0.5% is labeled for seasonal-allergy itching and inflammation after cataract extraction. Allergy dosing is one drop in affected eyes four times daily. The cataract regimen starts 24 hours after surgery, one drop four times daily through the first two postoperative weeks. Store at 15-25°C, protected from light. Use below age two is unestablished.
Keep Acular LS limited to its prescribed course
Acular LS ketorolac 0.4% is labeled for pain and burning after corneal refractive surgery: one drop in the operated eye four times daily as needed, for up to four days. Its label does not establish post-cataract efficacy. Store at 15-25°C away from light; the bottle may remain usable until its expiration, but this does not extend the treatment course. Use below age three is unestablished.
Use Acuvail as a single-dose product
Acuvail ketorolac 0.45% treats cataract-surgery pain and inflammation. Give one drop in the affected eye twice daily starting one day before surgery, including surgery day, through the first two postoperative weeks. Use each preservative-free vial immediately and discard the remainder. Keep vials in their folded-closed light-protective pouch at 15-30°C. Use below age two is unestablished.
Monitor ketorolac beyond pain relief
For these ketorolac drops, separate other eye medicines by at least five minutes and do not instill with contact lenses in place. Review aspirin/NSAID sensitivity, asthma and bleeding risk. Topical NSAIDs can delay healing, especially with topical steroids, and can cause serious corneal injury. Epithelial breakdown requires immediate discontinuation and close ophthalmic monitoring. Dry eye, diabetes, rheumatoid arthritis and complicated or repeated eye surgery increase concern. Do not extend a surgical course without reassessment. Pregnancy and breastfeeding require product-specific review; Acular labeling advises avoiding late-pregnancy use.
Distinguish the nepafenac schedules
Ilevro 0.3% and Nevanac 0.1% suspensions treat cataract-surgery pain and inflammation. Ilevro uses one drop once daily; Nevanac uses one drop three times daily. Both begin one day before surgery, include surgery day, and continue through the first two postoperative weeks. Ilevro also specifies an additional drop 30-120 minutes before surgery. Shake well before each dose; separate other eye medicines by at least five minutes. Store both at 2-25°C and protect Ilevro from light. Their surgical-use labels advise against using the same bottle for both eyes.
Apply nepafenac safety boundaries
Ingredient or other NSAID hypersensitivity contraindicates these products. Do not instill with contact lenses in place. Review bleeding risk, delayed healing and corneal vulnerability; epithelial breakdown requires immediate discontinuation and close eye-specialist follow-up. Avoid extending treatment without review. Both labels advise avoiding late-pregnancy use, and safety and effectiveness below age ten are unestablished. Nepafenac is converted in ocular tissue to amfenac, which inhibits prostaglandin production; this mechanism does not make the two strengths interchangeable.
Use ophthalmic NSAIDs for defined roles
Topical NSAIDs have perioperative and selected inflammatory indications. They are not routine cosmetic red-eye treatments. Corneal disease, epithelial defects, concurrent topical exposure, surgery, healing, and duration affect risk, including rare but serious corneal complications.
Escalate failure instead of extending blindly
Worsening pain, photophobia, discharge, reduced vision, corneal change, pressure symptoms, or failure to improve requires reassessment of diagnosis and treatment. Extending potent local therapy without examination can convert a reversible problem into lasting injury.
Quick check
Checking for saved practice…
Lesson
Ocular Redness and Medication-Induced Injury
Redness relief changes appearance, while medication injury can affect the surface, pressure, lens, retina, optic nerve, color, field, or vision. Cause and structure determine urgency.
- Vasoconstrictor limits
- Rebound redness
- Surface toxicity
- Retinal surveillance
- Sudden visual change
Allergy, infection, dryness, inflammation, trauma, and pressure differ
Connect dose, duration, route, and ocular structure
Use drug-specific surveillance before symptoms become permanent
Vision loss, field change, color change, or pain demands action
Treat the cause, not the color
Ocular vasoconstrictors can reduce visible hyperemia from minor irritation but do not diagnose infection, allergy, dryness, inflammation, trauma, or pressure disease. Repeated use can add surface irritation or rebound. Persistent, recurrent, unilateral, painful, light-sensitive, or vision-changing redness needs reassessment.
Identify antihistamine combinations separately
Naphcon-A combines naphazoline 0.025% for redness with pheniramine 0.3% for allergic itching. Ages six and older use one or two drops up to four times daily; younger children need medical advice. Ask a clinician before use with narrow-angle glaucoma, heart disease, hypertension or urinary difficulty. Remove lenses. Store at 20-25°C protected from light. The antihistamine component distinguishes this product from a redness-only vasoconstrictor.
Check the exact Visine or Clear Eyes product
Visine Red Eye Comfort contains tetrahydrozoline 0.05%. Its label permits one or two drops up to four times daily from age six; ages two to five require medical advice, and use below two is prohibited. Clear Eyes Redness Relief instead combines naphazoline 0.012% with glycerin 0.25%, using one or two drops up to four times daily. Its reviewed label gives no pediatric age cutoff; do not infer suitability for infants or substitute another brand’s age instructions. Both require lens removal and clinician advice with narrow-angle glaucoma, and are stored at 20-25°C.
Avoid prolonged whitening and prevent ingestion
These naphazoline and tetrahydrozoline labels warn that overuse can increase redness and temporarily enlarge pupils. Stop and obtain assessment for pain, vision change, worsening or persistent redness, or symptoms lasting more than 72 hours. Do not delay assessment of urgent symptoms until that deadline. Keep bottles away from children; swallowing requires immediate medical or poison-center advice. Naphcon-A specifically warns of coma and markedly reduced body temperature after accidental ingestion by children.
Read the redness product's own directions
Lumify brimonidine tartrate 0.025% treats minor-irritation redness, not glaucoma. Its current multidose label directs ages five and older to use one drop every six to eight hours, at most four times daily; younger children need a doctor’s advice. Remove lenses and wait at least ten minutes before reinsertion, and separate other eye products by five minutes. Stop and seek medical advice for pain, vision change, continuing redness or irritation, or worsening or persistence beyond three days. These limits do not establish that an undiagnosed red eye is suitable for self-care.
Map medication effects to ocular structures
Anticholinergic exposure can blur vision or worsen angle risk in susceptible patients. Corticosteroids can affect pressure and lens. Amiodarone, ethambutol, linezolid, topiramate, digoxin, PDE5 inhibitors, isotretinoin, voriconazole, and other agents have distinct ocular patterns. Timing, dose, duration, route, and comorbidity shape causality.
Check hydroxychloroquine dose and risk
AAO recommends no more than 5 mg/kg/day using actual weight, with additional dose caution in severe obesity. Review duration, renal disease, tamoxifen and older age at initiation with the treating team.
Screen before visual symptoms
Arrange baseline fundus examination, OCT and fundus autofluorescence (FAF) soon after starting hydroxychloroquine. Annual OCT and wide-pattern FAF may be deferred during the first five years only without significant risk factors. Examine both parafoveal and pericentral regions; fields and multifocal electroretinography provide confirmation.
Include chloroquine in retinal surveillance
Chloroquine also can cause irreversible retinal injury. Its label calls for a baseline eye examination within the first year, including corrected acuity, visual fields and spectral-domain OCT. Renal impairment, tamoxifen, macular disease, higher dose and longer exposure increase risk. Significant risk factors require annual examinations; low-risk patients may defer annual testing until year five. Ophthalmology should select fields that capture the relevant retinal distribution. Suspected ocular toxicity requires prompt prescriber and eye-specialist action to discontinue chloroquine and continue surveillance: damage can progress after withdrawal. Do not substitute hydroxychloroquine dosing limits for chloroquine instructions.
Do not promise reversibility
Severe hydroxychloroquine retinopathy can progress after withdrawal. Early abnormalities require ophthalmology and prescriber discussion of continued treatment versus cessation; normal visual acuity alone does not exclude toxicity.
Recognize topiramate-related angle closure
New eye pain or sudden blur during topiramate treatment requires immediate eye assessment. Supraciliary fluid can shift the lens-iris complex forward, causing acute myopia and secondary angle closure, usually within the first month; children are also susceptible. The treating physician should arrange rapid discontinuation when this syndrome is suspected. Separately, visual-field defects may occur without raised pressure, so a normal pressure reading does not dismiss new visual symptoms.
Keep vigabatrin surveillance scheduled
Vigabatrin can permanently constrict peripheral vision and sometimes impair central vision. Arrange assessment before treatment or within four weeks of starting, at least every three months during therapy, and about three to six months after stopping. Testing does not guarantee prevention; symptoms may emerge late and damage can worsen after withdrawal. When testing is unreliable or impossible, the specialist must individualize evaluation and explain its limits. Coordinate benefit-risk reassessment and any withdrawal with the seizure-treatment team.
Disclose past alpha-blocker use before eye surgery
Tamsulosin and other alpha blockers can be associated with intraoperative floppy iris syndrome during cataract or glaucoma surgery. Tell the ophthalmic surgeon about both current and previous use, even months after stopping. A preoperative drug holiday has not been established to eliminate the risk. Coordinate the medication plan with the prescriber and surgeon; initiating tamsulosin when this surgery is scheduled is not recommended by its label.
Separate amiodarone deposits from optic neuropathy
Amiodarone commonly causes corneal microdeposits. Deposits without symptoms do not alone justify dose reduction or withdrawal. New acuity loss or reduced peripheral vision needs prompt ophthalmic evaluation and prescriber review because optic neuropathy or neuritis may cause permanent loss. The label recommends regular fundus and slit-lamp examinations. Do not attribute new symptoms to benign deposits without examination or independently abandon needed arrhythmia treatment.
Monitor ethambutol acuity and color discrimination
Obtain baseline visual acuity and color testing, then ask about visual changes and repeat color testing monthly during treatment under ATS/CDC/IDSA guidance. The label also calls for periodic acuity testing, monthly above 15 mg/kg/day, with each eye assessed separately and together. Review renal function and dose. New blur, scotoma or color difficulty requires prompt assessment and coordination with the TB team to discontinue ethambutol when toxicity is suspected; recovery is not guaranteed.
Investigate visual symptoms during any linezolid course
Linezolid-associated optic and peripheral neuropathy is reported mainly beyond 28 days, but blurred vision can occur during shorter treatment. New acuity, color or field changes require prompt ophthalmic evaluation regardless of duration. The label calls for visual-function monitoring in everyone receiving at least three months of therapy and in anyone with new visual symptoms. If neuropathy occurs, the treatment team must reconsider continued exposure against infection-control needs.
Treat sudden vision loss with PDE5 inhibitors as urgent
Sildenafil can transiently alter color discrimination, including blue-green perception, through retinal PDE6 effects. Sudden loss of vision in either eye is a different warning: stop PDE5 inhibitors and seek immediate medical attention. NAION has been reported in temporal association and can cause permanent loss, although the label says available reports and observational associations do not establish causation. Do not dismiss a new field or acuity deficit as an expected color effect.
Protect night vision during isotretinoin treatment
Isotretinoin can cause dry eyes, reduced contact-lens tolerance, corneal changes and impaired night vision. Night-vision loss may begin suddenly and can persist after treatment stops. Visual difficulty calls for discontinuation and ophthalmic examination under the label, with prompt contact with the prescriber. Avoid night driving when vision is affected; lubricating drops alone do not address a new loss of visual function.
Monitor vision during prolonged voriconazole use
Voriconazole commonly causes visual disturbance, altered color perception or photophobia. Prolonged events, including optic neuritis and papilledema, have also been reported. If treatment extends beyond 28 days, monitor acuity, visual fields and color perception. New, persistent or worsening symptoms warrant clinical review rather than assuming every visual effect is brief and harmless.
Connect digoxin visual symptoms to systemic toxicity
Blur, halos or yellow-green color changes can accompany digoxin toxicity, especially alongside nausea, vomiting, anorexia or rhythm disturbance. Arrange prompt clinical evaluation, including cardiac assessment, renal function, electrolytes and a properly interpreted digoxin concentration. Toxicity can occur below 2 ng/mL; neither a single concentration nor absence of color symptoms excludes it. Severe symptoms or suspected arrhythmia require emergency assessment, not treatment with an eye drop.
Act on sudden or progressive change
Sudden vision loss, new field defect, color change, severe blur, halos with systemic symptoms, eye pain, photophobia, flashes, floaters, or rapidly progressive symptoms requires prompt evaluation. Medication review supports the assessment but should not delay urgent eye care.
Quick check
Checking for saved practice…
Lesson
Ophthalmic Dosage Forms and Dose Delivery
Solutions, suspensions, gels, ointments, emulsions, and single-use products require different preparation, order, spacing, and disposal. Precise delivery improves effect and limits systemic exposure.
- Solution and suspension
- Prescribed drop count
- Conjunctival sac
- Punctal occlusion
- Product sequence
Check eye, product, formulation, seal, and expiration
Avoid the cornea and keep the tip sterile
Reduce nasolacrimal drainage and systemic exposure
Separate products and put ointment last
Prepare the exact dosage form
Wash and dry hands, verify the right product and eye in plain language, inspect seal and expiration, and follow label-specific shaking, warming, priming, storage, and single-use instructions. Suspensions usually require shaking, while emulsions and gels have product-specific preparation.
Deliver the prescribed dose into the conjunctival sac
Tilt the head, pull the lower lid gently, look upward, and hold the tip above the sac without contact. Follow the prescribed product-specific drop count; a one-drop technique is common, but some labels allow one to two drops. Do not add extra drops to compensate for uncertainty or replace an explicit regimen with a universal rule. Close the eye gently rather than squeezing or blinking repeatedly.
Apply ointment to the prescribed site
For an ophthalmic ointment prescribed into the eye, gently lower the lid and place the prescribed ribbon in the pocket without touching the tube tip to the eye or skin. Close the eye gently afterward. A lid-margin treatment may instead require application to the affected eyelid after cleaning; confirm that site rather than assuming every ointment goes into the eye. Use the exact product amount and technique. Temporary blur can follow application: wait for clear vision before driving or other vision-dependent tasks. Avoid contact lenses during an eye infection and follow the product-specific lens restrictions.
Reduce drainage when appropriate
Gentle eyelid closure and pressure at the inner canthus can reduce nasolacrimal drainage and systemic absorption. This matters when systemic adverse effects are important. Do not press on an injured eye, and use the duration and technique appropriate to the prescribed product and patient.
Sequence multiple products
Use product-label spacing, commonly at least five minutes between different drops, to reduce washout. Use gels and ointments after thinner drops unless the label or prescriber directs otherwise. Write the schedule when several products or different eyes are involved.
Quick check
Checking for saved practice…
Lesson
Sterility, Contact Lenses, and Preservatives
Ophthalmic products bypass natural defenses. Sterility, reliable sourcing, recall awareness, tip clearance, lens removal, and preservative burden are clinical safety issues.
- Sterile product
- Tip contamination
- FDA recalls
- Contact lenses
- Preservative-free handling
Never touch the eye, skin, hands, clothing, or surfaces
Follow exact-label wait time or infection-related no-wear plan
Consider surface tolerance when exposure is frequent
Check sterility, seals, reliable sourcing and current FDA alerts
Treat sterility as a therapeutic requirement
FDA emphasizes that eye drops bypass natural defenses and must be sterile. Wash hands and never touch the tip to the eye, surrounding tissue, fingers, clothing, or another surface. Do not share products. Stop and seek care for discharge, pain, vision change, or unexpected discomfort after use.
Verify source, seal, and alerts
Use reliable products with intact seals, clear labeling, current expiration, correct storage, and no recall or warning. FDA advises against unapproved homeopathic eye products, iris-color claims, and products marketed OTC for serious diseases such as glaucoma, cataract, retinopathy, or macular degeneration.
Build contact-lens instructions into the plan
Remove lenses before instillation when the exact label requires it and wait the labeled interval before reinsertion. Infection, corneal injury, surgery, and some products require a longer no-lens period. Never rinse lenses or cases with tap water, and replace contaminated supplies.
Make reusable-lens hygiene specific
Wash and thoroughly dry hands before handling lenses. Remove lenses before showering or swimming and avoid sleeping in them unless the eye-care prescriber specifically directs it. For a multipurpose care system, rub and rinse lenses with the recommended disinfecting solution and use fresh solution each time; never top off used solution. Rub and rinse the case with solution, dry with a clean tissue, and store upside down with caps off. Replace the case at least every three months and follow the lens replacement schedule. Carry backup glasses and remove lenses if discomfort develops.
Separate cleaning from disinfection
Saline rinses and daily cleaners do not disinfect lenses. Hydrogen peroxide systems require their supplied neutralizing case and the full product-labeled neutralization time before insertion. Never put unneutralized peroxide in the eye or use it to rinse a lens immediately before insertion. Match the care system to soft versus rigid lenses; their products are not automatically interchangeable.
Balance preservatives and contamination
Preservatives reduce microbial growth in multidose containers but can irritate a compromised ocular surface. Frequent exposure or intolerance can favor preservative-free options. Preservative-free does not guarantee freedom from burning: the active drug, vehicle and ocular-surface condition can still cause discomfort. Single-use does not mean reusable: open only when needed and discard as labeled to preserve sterility.
Quick check
Checking for saved practice…
Lesson
Special Populations and Closed-Loop Follow-Up
Age, pregnancy, lactation, dexterity, cognition, access, and ocular history change both drug exposure and the reliability of self-care. Every plan needs a response window and exit.
- Neonatal urgency
- Pediatric technique
- Pregnancy and lactation
- Accessibility
- Return precautions
Treat neonatal and poorly examinable disease differently
Balance indication, evidence, and drainage reduction
Define a response window for every plan
Escalate whenever the pattern threatens vision
Use exact pediatric assessment and labeling
Do not stop after wax if impairment remains
Reassess acute otitis externa if not improving in 48 to 72 hours
Act on mastoid, neurologic, invasive, or sudden findings
Use age-specific pediatric triage
Neonatal conjunctivitis can be time-sensitive and is not routine pink eye. Children with pain, photophobia, reduced vision, trauma, severe swelling, fever, contact-lens risk, or an unreliable examination need prompt evaluation. Verify pediatric labeling and caregiver administration for every product.
Individualize pregnancy and lactation
Topical ocular delivery can still reach systemic circulation through nasolacrimal drainage. Confirm the indication, product-specific pregnancy and lactation evidence, alternatives, treatment duration, and disease risk. Gentle occlusion can reduce exposure when appropriate, but benefit-risk assessment remains necessary.
Design for real-world administration
Low vision, arthritis, tremor, cognition, language, cost, complicated schedules, and bottle stiffness can undermine delivery. Use plain-language laterality, large-print or tactile organization, dose aids, caregiver support, written sequencing, and return demonstration rather than assuming adherence.
Close every self-care loop
Set an expected course and a stop rule. Pain, photophobia, reduced or changing vision, corneal change, severe swelling, trauma, chemical exposure, worsening discharge, systemic illness, persistence, recurrence, treatment intolerance, or contact-lens complications require reassessment at urgency matched to the finding.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 175 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- MedlinePlus. Bacitracin ophthalmic administration and precautions
- FDA. Orange Book, 46th edition (2026), discontinued Alomide listing, page 6-324
- DailyMed. Naphcon-A Drug Facts
- DailyMed. Visine Red Eye Comfort Drug Facts
- DailyMed. Clear Eyes Redness Relief Drug Facts
- DailyMed. Artificial Tears combination
- DailyMed. Systane Complete preserved
- CDC. Preventing eye infections with contacts
- CDC. Cleaning, disinfecting and storing contact lenses
- DailyMed. Erythromycin ophthalmic ointment
- DailyMed. Tobramycin ophthalmic solution
- DailyMed. Gentamicin ophthalmic solution
- DailyMed. Neomycin/polymyxin B/bacitracin ophthalmic ointment
- DailyMed. Sulfacetamide ophthalmic solution
- DailyMed. TobraDex ST prescribing information, March 2025
- DailyMed. Historical Novartis TobraDex suspension label; marketing ended 2024
- DailyMed. Sildenafil, ocular warning and color-discrimination effects
- DailyMed. Isotretinoin, section 5.13 ocular abnormalities
- DailyMed. Voriconazole, visual disturbances and monitoring
- DailyMed. Digoxin, toxicity and visual manifestations
- DailyMed. Amiodarone, section 5.5 visual impairment
- DailyMed. Ethambutol, ocular warnings and monitoring
- ATS/CDC/IDSA. Drug-susceptible tuberculosis guideline, optic neuritis
- DailyMed. Linezolid, section 5.2 optic neuropathy
- DailyMed. Topiramate, ocular warnings 5.1-5.2, revised May 2026
- DailyMed. Vigabatrin oral solution, boxed warning and vision monitoring
- DailyMed. Tamsulosin, intraoperative floppy iris syndrome warning
- DailyMed. Chloroquine phosphate: retinal warnings
- DailyMed. Acular prescribing information
- DailyMed. Acular LS prescribing information
- DailyMed. Acuvail prescribing information
- DailyMed. Ilevro prescribing information
- DailyMed. Nevanac prescribing information
- DailyMed. Pred Forte prescribing information
- DailyMed. Pred Mild prescribing information
- DailyMed. Maxidex prescribing information
- DailyMed. FML prescribing information
- DailyMed. FML Forte prescribing information
- DailyMed. Flarex prescribing information
- ASHP. Fluorometholone ophthalmic ointment discontinuation
- FDA. FML ointment archived labeling, 2013
- DailyMed. Lotemax 0.5% gel prescribing information
- DailyMed. Lotemax 0.5% ointment prescribing information
- DailyMed. Lotemax suspension prescribing information
- DailyMed. Lotemax SM prescribing information
- DailyMed. Diclofenac ophthalmic prescribing information
- DailyMed. Flurbiprofen ophthalmic prescribing information
- DailyMed. Prolensa prescribing information
- DailyMed. BromSite prescribing information
- DailyMed. Alembic bromfenac 0.09% prescribing information
- FDA. Historical Xibrom and Bromday dosing distinction
- DailyMed. Alrex prescribing information
- AAO. Hydroxychloroquine retinopathy screening: 2025 revision, published 2026
- DailyMed. Eysuvis prescribing information and instructions, November 2023
- DailyMed. Ozurdex prescribing information, March 2026
- DailyMed. Restasis MultiDose prescribing information and instructions, August 2025
- DailyMed. Tryptyr prescribing information and instructions, May 2025
- DailyMed. Miebo prescribing information, October 2025
- DailyMed. Tyrvaya prescribing information and instructions, July 2026
- DailyMed. Xiidra prescribing information and patient instructions, December 2023
- DailyMed. Vevye prescribing information, February 2026
- DailyMed. Restasis single-use emulsion, September 2024
- DailyMed. Cequa prescribing information
- NEI. Blepharitis, December 2024
- DailyMed. Xdemvy prescribing information
- FDA. Alomide historical labeling, 2003
- DailyMed. Harrow Zerviate prescribing information, December 2025
- DailyMed. Somerset epinastine prescribing information, March 2025
- DailyMed. Sandoz cromolyn 4%, February 2025
- DailyMed. Alocril historical labeling and marketing record
- DailyMed. Lastacaft OTC Drug Facts
- DailyMed. Alembic azelastine hydrochloride ophthalmic 0.05%
- DailyMed. Pataday 0.1% Drug Facts
- DailyMed. Pataday 0.2% Drug Facts
- DailyMed. Pataday 0.7% Drug Facts
- DailyMed. Zaditor ketotifen Drug Facts
- University of Iowa EyeRounds. Adult chlamydial conjunctivitis: clinical presentation and systemic care
- DailyMed. Zirgan prescribing information, January 2026
- University of Iowa EyeRounds. Herpes simplex keratitis: epithelial and immune disease
- CDC. Gonococcal infections: adult conjunctivitis
- CDC. Gonococcal infections among neonates
- CDC. Chlamydial infections: adult, pregnancy and neonatal pathways
- DailyMed. Ceftriaxone neonatal contraindications
- UCSF. Neonatal ceftriaxone safety criteria and ophthalmia exception
- DailyMed. Ciprofloxacin 0.3% Sandoz labeling, Redpharm listing
- DailyMed. Bausch + Lomb ofloxacin 0.3%, April 2023
- DailyMed. Vigamox prescribing information, January 2025
- DailyMed. Moxeza prescribing information, August 2021; historical presentation
- DailyMed. Besivance prescribing information, February 2022
- DailyMed. AzaSite 1% prescribing information and instructions, July 2024
- DailyMed. Bausch + Lomb polymyxin B/trimethoprim label, October 2025
- CDC. How to Treat Pink Eye
- DailyMed. Maxitrol suspension prescribing information, revised September 2024
- DailyMed. Lumify 0.025% multidose Drug Facts
- CDC Clinical Overview of Conjunctivitis
- FDA Eye Drop Safety Guidance
- American Academy of Ophthalmology Blepharitis Review
- American Academy of Ophthalmology Dry Eye Review
- American Academy of Ophthalmology Conjunctivitis Review
- National Eye Institute: Causes of Dry Eye
- TFOS DEWS II: Iatrogenic Dry Eye
- TFOS DEWS II: Pathophysiology
- FDA. Omnipred prescribing information, 2024
- DailyMed. Sandoz prednisolone acetate authorized generic
- Harrow. Vevye prescribing information and illustrated Instructions for Use